비아트리스

Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs; Viatris - Wikipedia; Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan; 비아트리스 - 위키백과, 우리 모두의 백과사전

Viatris - Wikipedia

Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend

Viatris - Wikipedia; Viatris unloads biosimilar business to partner Biocon for $3.3B; Viatris sells off biosimilars business in $3.3B deal; Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted - Investor Relations, Viatris; Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted - PR Newswire

Viatris 2022 Sustainability Report: Big Steps Toward a Smaller Footprint; Viatris 2022 Sustainability Report Highlights; Delivering on our Mission for Stakeholders - Viatris

Viatris - Wikipedia; Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023; Viatris taps new CEO to lead second phase of business revamp; Viatris Inc. (VTRS) Leadership & Management Team Analysis; Viatris appoints new CEO

Viatris - Wikipedia; Viatris Strategy and Business Model

Viatris sells off consumer, women's health drugs in asset sales; Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA - PR Newswire; Viatris to haul in $3.37B with 3 business divestures; Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA; Viatris's $6.94 Billion in Announced Divestitures, Cravath, Swaine & Moore LLP

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results - SEC.gov; Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]; Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] - PR Newswire; Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance; Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture - Investor Relations, Viatris; Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture - PR Newswire; Viatris Waves Goodbye To API Business - Citeline Insights

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris Inc. (VTRS) Leadership & Management Team Analysis